Abstract
Background: The experience in clinical practice with brentuximab vedotin (BV), an antibody targeting CD30, is sparse and our knowledge about this drug in primary cutaneous T-cell lymphoma (CTCL) comes mainly from clinical trials. We want to share our clinical experience with BV in the treatment of advanced stage C30-positive mycosis fungoides.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
